Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Net Cash Flow (2016 - 2021)

GT Biopharma (GTBP) has disclosed Net Cash Flow for 12 consecutive years, with -$714000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Net Cash Flow fell 114.43% to -$714000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $29.7 million, a 463.71% increase, with the full-year FY2025 number at $2.9 million, down 3.04% from a year prior.
  • Net Cash Flow was -$714000.0 for Q4 2021 at GT Biopharma, up from -$3.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $22.3 million in Q1 2021 to a low of -$3.8 million in Q3 2021.
  • A 5-year average of $2.2 million and a median of $49000.0 in 2019 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 1497.04% in 2017, then soared 96873.91% in 2021.
  • GT Biopharma's Net Cash Flow stood at -$2.2 million in 2017, then soared by 206.4% to $2.3 million in 2018, then crashed by 112.42% to -$285000.0 in 2019, then surged by 1835.79% to $4.9 million in 2020, then crashed by 114.43% to -$714000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Net Cash Flow are -$714000.0 (Q4 2021), -$3.8 million (Q3 2021), and $12.0 million (Q2 2021).